S961 Risk of New or Recurrent Cancer After Vedolizumab or Ustekinumab Exposure in Patients With Inflammatory Bowel Disease and Previous Cancer. (October 2021) - Zenger, Cameron; Hong, Simon J.; Pecoriello, Jillian; Pang, Alice S.; Vallely, Margaret; Hudesman, David; Chang, Shannon; Axelrad, Jordan